Drugs / CMVsu vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05089630 | Oct 2021 → Apr 2025 | cytomegalovirus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMVsu vaccine | “The purpose of this study is to assess the safety, reactogenicity and immune response of the candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a...” NCT05089630 ↗ |
| Modality | Vaccine | “candidate CMV recombinant protein subunit (CMVsu) vaccine” NCT05089630 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05089630 ↗ |